Healthcare / BiotechnologyNasdaqGM
$23.87
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-41.6M · quality 29.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+1644.5%
FCF CAGR
—
FCF margin
238.7%
FCF / Net income
-2.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $46.0M · net income $-48.9M · FCF $109.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $46.0M | $46.0M | $1.1M | $151000.00 |
| Net Income | $-48.9M | $-48.9M | $-71.8M | $4.2M |
| EBITDA | $-66.7M | $-66.7M | $-79.4M | $2.9M |
| EPS | -1.10 | -1.10 | -7.26 | 0.29 |
| Operating Margin | -148.6% | -148.6% | -7518.4% | 1374.2% |
| Net Margin | -106.4% | -106.4% | -6678.9% | 2768.2% |
| Cash Flow | ||||
| Free Cash Flow | $109.7M | $109.7M | $-69.6M | $-41.6M |
| Returns | ||||
| ROE | -12.8% | -12.8% | -17.1% | -10.9% |
| Growth & Yield | ||||
| Revenue Growth | 4174.5% | 4174.5% | 611.9% | — |
| EPS Growth | 84.8% | 84.8% | -2603.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.